EAM
MRTX

Eagle Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Eagle Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-270,209
Closed -$18.9M – 570
2022
Q3 		$18.9M Buy
270,209
+1,666
+0.6% +$123K 0.12% 171
2022
Q2 		$18M Buy
268,543
+6,141
+2% +$391K 0.11% 185
2022
Q1 		$21.6M Buy
262,402
+3,594
+1% +$368K 0.11% 193
2021
Q4 		$38.4M Sell
258,808
-698
-0.3% -$108K 0.17% 166
2021
Q3 		$45.9M Buy
+259,506
New +$41.8M 0.21% 160
2021
Q2 		– Sell
-225,534
Closed -$40.5M – 622
2021
Q1 		$40.5M Buy
225,534
+5,563
+3% +$1.1M 0.18% 179
2020
Q4 		$48.3M Sell
219,971
-27,759
-11% -$6M 0.27% 134
2020
Q3 		$41.1M Sell
247,730
-27,424
-10% -$3.75M 0.21% 163
2020
Q2 		$31.6M Sell
275,154
-14,334
-5% -$1.39M 0.18% 178
2020
Q1 		$22.3M Buy
289,488
+2,284
+0.8% +$205K 0.14% 198
2019
Q4 		$37M Buy
+287,204
New +$27.7M 0.18% 195

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Eagle Asset Management's MRTX Position: Q4 2022 in Review

Eagle Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2022, closing a stake of 270,209 shares — an estimated $18.9M sold.

Eagle Asset Management first reported a position in MRTX in Q4 2019 and held it in 11 quarters. The position peaked at $48.3M in Q4 2020. 233 funds tracked by Wall St. Rank hold MRTX as of Q4 2022.

  • Eagle Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Eagle Asset Management sold 270,209 Mirati Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $18.9M.
  • Eagle Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
  • Eagle Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $48.3M in Q4 2020.
  • 233 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Eagle Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.